APVO451 / Aptevo Therap - LARVOL DELTA

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules (ACCESS Newswire) - "Aptevo Therapeutics Inc...announced expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple, additional solid tumor types with significant unmet needs."

New molecule • Prostate Cancer • Solid Tumor